Jove
Visualize
Contact Us

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage.

Scientific reports·2026
Same author

Assessing the Fragility of Statistically Significant Outcomes in Randomized Controlled Trials of Minimally Invasive Glaucoma Surgery (MIGS).

American journal of ophthalmology·2026
Same author

Stable isotope evidence of anthropocene disruption in African softshell turtle foraging.

PloS one·2026
Same author

An unclean slate, discrepancies between food input and recovered protein signal from experimental foodcrusts.

PloS one·2025
Same author

An extensive archaeological dental calculus dataset spanning 5000 years for ancient human oral microbiome research.

Data in brief·2025
Same author

From Aortic Stenosis to Cardiomyopathy: The Hidden Impact of Undiagnosed Acommissural Unicuspid Aortic Valve.

JACC. Case reports·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 19, 2026

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.5K

Bispecific FpFs: a versatile tool for preclinical antibody development.

Matthew Collins1, Nkiru Ibeanu2,3, Wiktoria Roksana Grabowska4

  • 1School of Health, Sport and Bioscience, University of East London London UK.

RSC Chemical Biology
|September 30, 2024
PubMed
Summary

We developed bispecific antibody mimetics called bsFpFs using novel conjugation methods. These bsFpFs demonstrate independent binding of each fragment, enabling predictable binding profiles for preclinical antibody development.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
06:53

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

3.1K

Related Experiment Videos

Last Updated: Jun 19, 2026

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.5K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
06:53

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

3.1K

Area of Science:

  • Bioconjugation Chemistry
  • Protein Engineering
  • Antibody Mimetic Development

Background:

  • Fragment-PEG-Fragment (FpF) molecules serve as binding mimetics for immunoglobulin G (IgG).
  • Traditional FpFs utilize di(bis-sulfone) reagents for disulfide rebridging conjugation with accessible disulfides on antibody fragments (Fabs).
  • Sourcing bispecific antibodies for preclinical research can be challenging, necessitating alternative strategies.

Purpose of the Study:

  • To prepare bispecific FpFs (bsFpFs) as potential bispecific antibody mimetics for preclinical development.
  • To explore and improve synthetic routes for bsFpFs, including sequential conjugation and protein conjugation-ligation approaches.
  • To evaluate the binding characteristics of bsFpFs and their potential for predictable binding profiles.

Main Methods:

  • Synthesis of bsFpFs using di(bis-sulfone) reagents via sequential conjugation of Fabs.
  • Investigation of asymmetric conjugation reagents (bis-sulfone bis-sulfide) for improved bsFpF synthesis.
  • Development of a protein conjugation-ligation approach using reagents with bis-sulfone and ligation moieties (e.g., TCO, Tz) for bsFpF preparation.
  • Surface Plasmon Resonance (SPR) analysis to determine binding kinetics (k_a, k_d) of bsFpFs and their Fab components.

Main Results:

  • Bispecific FpFs (bsFpFs) were successfully synthesized using both sequential conjugation and conjugation-ligation strategies.
  • The use of asymmetric reagents and conjugation-ligation approaches yielded bsFpFs with comparable efficiency to di(bis-sulfone) reagents.
  • SPR studies showed minimal differences in dissociation rates (k_d) for Fabs within bsFpFs compared to their PEG-Fab conjugates.
  • Slower association rates (k_a) were observed for Fabs in bsFpFs, potentially due to mass effects influencing SPR measurements.

Conclusions:

  • The developed bsFpFs function as effective bispecific antibody mimetics.
  • Each Fab in a bsFpF binds its target independently, suggesting predictable binding behavior.
  • bsFpF binding profiles can be reliably estimated from their corresponding PEG-Fab conjugates, facilitating preclinical antibody development.